Steep Hill, a medical cannabis testing and analytics firm, named Andrew Rosenstein as interim CEO following the retirement of Jmichaele Keller.
Rosenstein became CEO of Steep Hill Maryland when the Berkeley, Calif.–based company launched locally in 2016. That lab, located in Columbia, aims to complete its accreditation process by the end of the month, according to Steep Hill. Rosenstein has since also become CEO of the company’s operations in D.C. and Pennsylvania. He also serves as director of University of Maryland St. Joseph Medical Center.
Steep Hill operates services to measure safety and purity of cannabis for distributors and producers of medical cannabis in 10 states and a total of nine countries. Along with the CEO transition, the company also said investor Merida Capital Partners increased its stake in the company. Terms were not disclosed.
READ FULL ARTICLE HERE
